Ieq Capital LLC Acquires New Stake in Sarepta Therapeutics, Inc. $SRPT

Ieq Capital LLC acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, Holdings Channel reports. The institutional investor acquired 131,822 shares of the biotechnology company’s stock, valued at approximately $2,369,000.

Other hedge funds also recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics during the third quarter worth about $25,000. Meeder Asset Management Inc. purchased a new position in Sarepta Therapeutics during the second quarter worth about $27,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Finally, Allworth Financial LP lifted its position in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,721 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 4.4%

NASDAQ:SRPT opened at $18.92 on Wednesday. The company has a market capitalization of $2.00 billion, a PE ratio of -6.52, a price-to-earnings-growth ratio of 0.27 and a beta of 0.23. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $25.32. The stock has a fifty day simple moving average of $17.53 and a 200-day simple moving average of $18.26.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The business had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same period in the previous year, the firm earned $2.02 EPS. The business’s revenue for the quarter was down 34.3% compared to the same quarter last year. On average, equities research analysts expect that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SRPT has been the topic of several recent analyst reports. Zacks Research upgraded Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a research note on Wednesday, August 19th. HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wall Street Zen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, July 9th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $25.06.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.